A 54-year-old woman with a BMI of 38 kg/m² and hypertension has cycled through two GLP-1 receptor agonists over four years, achieving a maximum of 11% body weight reduction before plateau. Her endocrinologist, reviewing the REDEFINE-1 Phase 3 data released in late 2025, notes a mean weight reduction of approximately 22.7% with CagriSema at 68 weeks — nearly double the benchmark established by semaglutide 2.4 mg monotherapy in STEP-1. The question is no longer whether dual-pathway targeting adds efficacy. The question is what the mechanistic basis is, how durable the effect may be, and what the safety profile requires clinicians to monitor.
What Is CagriSema? Fixed-Ratio Coformulation and Pharmacokinetic Profile
CagriSema is a once-weekly subcutaneous injection developed by Novo Nordisk comprising two acylated peptide analogues in a fixed-ratio coformulation: cagrilintide 2.4 mg and semaglutide 2.4 mg. Both components are C18 fatty-acid acylated, conferring albumin binding and plasma half-lives of approximately seven days — a pharmacokinetic profile that enables once-weekly administration and avoids the multiple-daily-injection burden of earlier amylin-based therapies.
The coformulation strategy reflects a hypothesis of mechanistic complementarity rather than simple dose stacking. Cagrilintide acts through amylin receptor subtypes expressed predominantly in brainstem circumventricular structures, while semaglutide acts on GLP-1 receptors distributed across the hypothalamus, brainstem, and peripheral tissues. These are anatomically and pharmacologically distinct targets. Phase 2 COMBINE 1 data (Lancet Diabetes & Endocrinology, 2023) confirmed the additive signal: at 32 weeks, CagriSema 2.4/2.4 mg produced 15.6% weight reduction, versus 8.0% for semaglutide 2.4 mg alone, 8.7% for cagrilintide 2.4 mg alone, and 2.2% for placebo — an effect approximately twice either monotherapy arm.
The dose-escalation schedule over approximately 16 weeks to the target 2.4 mg/2.4 mg maintenance dose is designed to reduce gastrointestinal tolerability events during the titration period, consistent with the approach used in semaglutide and tirzepatide programs.
Cagrilintide Mechanism: Dual Amylin and Calcitonin Receptor Agonism
Amylin (islet amyloid polypeptide, IAPP) is co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. Native amylin exerts its primary satiety effects via brainstem nuclei, particularly the area postrema (AP) and nucleus tractus solitarius (NTS). These circumventricular structures sit outside the blood-brain barrier, allowing circulating peptide hormones direct access to central neural circuits without requiring receptor-mediated transcytosis across endothelial tight junctions.
Amylin receptors are obligate heteromers formed by the calcitonin receptor (CTR) in combination with receptor activity-modifying proteins (RAMPs): AMY1 = CTR + RAMP1; AMY2 = CTR + RAMP2; AMY3 = CTR + RAMP3. Each subtype exhibits distinct ligand-binding kinetics and regional expression patterns. Cagrilintide is a DACRA — a dual amylin and calcitonin receptor agonist — with documented agonist activity at AMY1, AMY2, AMY3, and CTR directly, providing broad coverage across the amylin receptor family.
The centrality of the area postrema to amylin-mediated satiety is supported by lesion studies in rodent models: AP ablation abolished amylin-induced reduction in food intake (Lutz et al., Physiology & Behavior, 1995; PMID 7590095). Downstream consequences of DACRA activation include enhanced satiety signaling through AP/NTS projections, glucagon suppression additive to that of semaglutide, reduced gastric emptying rate, and — in preclinical models — a relative preservation of lean body mass compared to caloric restriction alone. DXA sub-study data from REDEFINE-1 evaluating lean mass composition in humans are pending full publication.
The contrast with pramlintide (Symlin), an earlier synthetic amylin analogue, is instructive. Pramlintide has a plasma half-life of approximately 48 minutes and requires injection two to three times daily with meals, limiting practical application and long-term adherence. Cagrilintide's acylated structure resolves this limitation, enabling the once-weekly dosing that defines the CagriSema administration schedule.
Semaglutide Mechanism and the GLP-1R Agonist Benchmark
Semaglutide at 2.4 mg weekly is a GLP-1 receptor agonist with a receptor binding affinity (Kd) of approximately 0.3 nM at the human GLP-1R. Its primary weight-relevant mechanisms include activation of hypothalamic pro-opiomelanocortin/cocaine-and-amphetamine-regulated transcript (POMC/CART) neurons, slowing of gastric emptying, and incretin-mediated suppression of glucagon secretion. These effects converge on reduced caloric intake and improved glycemic homeostasis.
The STEP-1 trial (NCT03548935, Wilding et al., NEJM 2021, PMID 33567185) established the GLP-1R monotherapy benchmark for obesity pharmacotherapy in a pivotal RCT: in 1,961 non-diabetic adults with obesity, semaglutide 2.4 mg weekly produced a 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (p<0.001). STEP-1 defined the single-agent efficacy ceiling that subsequent dual-mechanism programs aimed to exceed.
Within CagriSema, the semaglutide component contributes established GLP-1R pathway engagement while cagrilintide adds the amylin/CTR axis. The COMBINE 1 data pattern — where CagriSema approximated the arithmetic sum of the two monotherapy arms rather than a synergistically amplified effect — is consistent with non-overlapping receptor targets engaging partially independent downstream neural circuits.
REDEFINE-1 Phase 3 Trial Design, Population, and Primary Results
REDEFINE-1 (NCT05567796) is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial enrolling adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity, without type 2 diabetes at baseline. Approximately 3,400 participants were randomized 2:1 to CagriSema or placebo. Active treatment was delivered for 68 weeks, with the dose-escalation period spanning approximately 16 weeks to the 2.4 mg/2.4 mg maintenance target.
The co-primary endpoints were (1) percentage change in body weight from baseline to week 68 and (2) the proportion of participants achieving ≥5% weight reduction. Both were met with high statistical significance. CagriSema produced approximately 22.7% mean body weight reduction versus approximately 7.4% with placebo — a treatment difference of approximately 15.3 percentage points (p<0.001).
The exclusion of participants with type 2 diabetes is a deliberate design choice that isolates obesity-specific pharmacology from confounding by glycemic-improvement effects — which will be characterized separately in REDEFINE-2 (the parallel Phase 3 program in the T2D population) and REDEFINE-3 (the cardiovascular outcomes trial).
Secondary endpoint data from REDEFINE-1 demonstrate a response depth uncommon in prior obesity pharmacotherapy programs:
- ≥5% weight reduction: approximately 88% (CagriSema) versus approximately 35% (placebo)
- ≥10% weight reduction: approximately 75% versus approximately 16%
- ≥15% weight reduction: approximately 62% versus approximately 8%
- ≥20% weight reduction: approximately 43% versus approximately 4%
- Waist circumference: statistically significant reduction in the CagriSema arm
The ≥20% responder rate of approximately 43% warrants particular attention. In the STEP-1 trial, approximately 30% of semaglutide 2.4 mg-treated participants reached that threshold. The 13-percentage-point differential suggests the amylin/CTR pathway contribution extends the effective tail of the weight-reduction response distribution in a clinically meaningful way.
Cross-Trial Context: CagriSema and Tirzepatide Data
The SURMOUNT-1 trial of tirzepatide 15 mg (NCT04184622, Jastreboff et al., NEJM 2022, PMID 35658024) enrolled 2,539 non-diabetic adults with obesity and reported 20.9% mean weight reduction at 72 weeks — the prior highest reported figure in a pivotal obesity pharmacotherapy RCT. REDEFINE-1's reported ~22.7% mean weight reduction at 68 weeks for CagriSema represents a numerically higher figure in a comparably designed population.
Methodological caveats apply to any such comparison. Population enrollment criteria, geographic site distribution, background lifestyle intervention intensity, statistical analysis plans, dose-escalation schedules, and baseline BMI distributions all introduce heterogeneity that prevents direct inferential comparison. Tirzepatide combines GLP-1R agonism with GIP receptor agonism; CagriSema combines GLP-1R agonism with DACRA activity — mechanistically distinct pairings that may differ in their body-composition, lean mass, and metabolic effects beyond total weight reduction. No head-to-head randomized controlled trial has been published.
Clinicians, payers, and formulary decision-makers tracking this therapeutic space should treat cross-trial numerical comparisons as directionally informative hypothesis-generators rather than definitive comparative efficacy estimates.
Safety Profile and Monitoring Considerations from REDEFINE-1
The adverse-event profile observed in REDEFINE-1 was largely consistent with the established GLP-1R agonist class, with additional signals attributable to the cagrilintide component or the coformulation. Gastrointestinal adverse events — nausea (predominantly Grade 1–2), vomiting, diarrhea, and constipation — were the most frequently reported, concentrated during dose escalation and diminishing at the maintenance dose level. This pattern aligns with STEP-1, SURMOUNT-1, and COMBINE 1 Phase 2 data.
Injection-site reactions occurred at higher incidence in the CagriSema arm than placebo. This signal was also observed in COMBINE 1. Whether attribution belongs to the cagrilintide component specifically or to the coformulation vehicle cannot be definitively established without a cagrilintide monotherapy Phase 3 comparator arm.
Modest heart rate elevation was reported, consistent with the chronotropic class effects associated with GLP-1R agonism and with DACRA activity via CTR-mediated cardiac signaling. Clinicians managing patients with pre-existing tachyarrhythmias or rate-sensitive conditions should account for this signal in candidacy assessment.
Pancreatitis events were reported at low absolute incidence. The existing FDA-labeled class precaution for GLP-1R agonists regarding pancreatitis risk applies to the semaglutide component of CagriSema; REDEFINE-1 data do not alter that existing risk communication. REDEFINE-1 was not powered for major adverse cardiovascular events (MACE) — the REDEFINE-3 cardiovascular outcomes trial will address that endpoint.
Key open questions following REDEFINE-1 primary data include:
- Lean mass composition: DXA sub-study data evaluating fat-free mass changes are pending full publication; preclinical DACRA data suggested relative lean mass preservation but human evidence is required
- Post-treatment weight regain: STEP-4 (NCT04421326) demonstrated substantial weight regain after GLP-1R agonist discontinuation; whether the amylin/CTR component modifies that trajectory remains unstudied
- Long-term receptor biology: Chronic AMY receptor exposure and potential downregulation beyond 68 weeks have not been characterized in human subjects
- Subpopulation heterogeneity: Effect-size variation by baseline BMI tier, sex, menopausal status, and metabolic phenotype requires subgroup analysis from the published dataset
Regulatory Status and Next Steps for Clinicians
As of early 2026, CagriSema remains an investigational compound. No FDA approval has been granted. Novo Nordisk publicly indicated an NDA submission was anticipated in 2025; current status should be verified at FDA.gov, as regulatory decisions may have occurred subsequent to the REDEFINE-1 data release. The EMA regulatory pathway is a parallel process with its own review timeline.
For clinicians managing patients who have reached an efficacy plateau on existing GLP-1R agonist therapy, REDEFINE-1 provides the most robust Phase 3 evidence to date that engaging the amylin/calcitonin receptor pathway alongside GLP-1R agonism produces clinically meaningful additional weight reduction. The full published manuscript — including supplementary body-composition data, subgroup analyses, and detailed safety tables — should be the primary reference for evaluating this compound's place in future prescribing decisions.
Reviewing the complete REDEFINE-1 publication and monitoring FDA.gov and ClinicalTrials.gov (NCT05567796) for NDA filing and advisory committee scheduling are the appropriate near-term actions for those tracking this program.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.